#1775120 Oral Semaglutide helps in maintaining β-cell function in patients with Recent-Onset Latent Autoimmune Diabetes in Adults: a 6 months Prospective Study

The effect of oral semaglutide on β-cell function in patients with latent autoimmune diabetes in adults (LADA) is not known. The objective of the study was to evaluate the effects of oral semaglutide on β-cell function in patients with recent-onset LADA. This was an open-label, randomized-controlled trial conducted in a specialized diabetes care unit in India. 28 recently diagnosed LADA patients were randomized to receive insulin therapy with semaglutide (n = 14) or without semaglutide (n = 14) for 6 months. Semaglutide was started at a dose of 3 mg daily and and after one month dose was increased to 7 mg daily. Insulin doses in both arms were titrated as required to achieve the target fasting glucose and post-prandial glucose. Fasting and 2-hour postprandial blood samples were obtained at baseline and after 2, 4, and 6 months of treatment to determine blood glucose, glycosylated hemoglobin, and C-peptide levels. There were no significant differences in glucose and glycosylated hemoglobin levels between the two groups during 6 months of follow-up. At 6 months, fasting C-peptide, 2-hour postprandial C-peptide, and increment in C-peptide (delta CP) levels were not different in Insulin plus semaglutide group (P >0 .05) compared with baseline, whereas in Insulin without semaglutide group the levels of fasting C-peptide, 2-hour postprandial C-peptide, and increment in C-peptide (delta CP) levels were significantly decreased compared with baseline (P <0.05). Levels of 2-hour postprandial C-peptide were higher in Insulin plus semaglutide group than Insulin without semaglutide group at 6 months (P < 0.05). Oral Semaglutide helps in maintaining β-cell function in patients with recent-onset Latent Autoimmune Diabetes in Adults when given with insulin when compared to insulin given alone.